GILEAD SCIENCES, INC.

For the period ended Jun 30, 2026. Filed Aug 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 6, 2026

GILD$170.87+0.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

Three Months Ended · Six Months Ended
	June 30,		June 30,
(in millions, except per share amounts)	2026	2025	2026	2025
Revenues:
Product sales	$7,627	$7,054	$14,574	$13,668
Royalty, contract and other revenues	176	27	189	81
Total revenues	7,803	7,082	14,763	13,749
Costs and expenses:
Cost of goods sold	1,579	1,501	3,023	3,041
Research and development expenses	1,764	1,491	3,136	2,870
Acquired in-process research and development expenses	11,183	61	11,290	315
In-process research and development impairments	1,750	190	1,750	190
Selling, general and administrative expenses	1,921	1,365	3,372	2,623
Total costs and expenses	18,197	4,608	22,571	9,038
Operating (loss) income	(10,394)	2,474	(7,808)	4,711
Interest expense	247	254	487	513
Other (income) expense, net	(387)	(208)	(621)	120
(Loss) income before income taxes	(10,254)	2,429	(7,674)	4,077
Income tax expense	242	468	801	802
Net (loss) income	$(10,496)	$1,960	$(8,475)	$3,275
Basic (loss) earnings per share	$(8.45)	$1.57	$(6.82)	$2.63
Diluted (loss) earnings per share	$(8.45)	$1.56	$(6.82)	$2.61
Shares used in basic (loss) earnings per share calculation	1,243	1,245	1,243	1,246
Shares used in diluted (loss) earnings per share calculation	1,243	1,255	1,243	1,257

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.